Flexing Your Muscles in Familial HypercholesterolemiaBest Practices for Screening, Diagnosis, and Management
Clinical Practice Guidelines
Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association.
Brown EE, Sturm AC, Cuchel M, et al. J Clin Lip idol. 2020;14(4):398-413.
The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association.
Gidding SS, Champagne MA, de Ferranti SD, et al. Circulation. 2015;132(22):2167-2192.
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Goldberg AC, Hopkins PN, Toth PP, et al. J Clin Lipidol. 2011;5(suppl 3):S1-S8.
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 Circulation. 2019;139(25):e1046-e1081.
2017 focused update of the 2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al J Am Coll Cardiol. 2017;70(14):1785-1822.
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS).
Mach F, Baigent C, Catapano AL, et al. Eur Heart J. 2020;41(1):111-188.
The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction.
Orringer CE, Blaha MJ, Blankstein R, et al. J Clin Lipidol. 2021;15(1):33-60.
Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel.
Sturm AC, Knowles JW, Gidding SS, et al. J Am Coll Cardiol. 2018;72(6):662-680.
Patient & Caregiver Resources
American Heart Association
Family Heart Foundation
National Lipid Association
Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels.
Bianconi V, Banach M, Pirro M. Trends Cardiovasc Med. 2021;31(4):205-215.
Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: The ODYSSEY HoFH trial.
Blom DJ, Harada-Shiba M, Rubba P, et al. J Am Coll Cardiol. 2020;76(2):131-142.
Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?
Brandts J, Dharmayat KI, Ray KK, Vallejo-Vaz AJ. Curr Opin Lipidol. 2020;31(3):111-118.
PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: the ODYSSEY KIDS study.
Daniels S, Caprio S, Chaudhari U, et al. J Clin Lipidol. 2020;14(3):322-330.
Impact of lipids on cardiovascular health: JACC Health Promotion Series.
Ference BA, Graham I, Tokgozoglu L, Catapano AL. J Am Coll Cardiol. 2018;72(23 Pt B):2980-2995.
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher.
Ginsberg HN, Rader DJ, Raal FJ, et al. Cardiovasc Drugs Ther. 2016;30(5):473-483.
Recognition and treatment of homozygous familial hypercholesterolemia by primary care physicians: a survey from the National Lipid Association.
Hemphill L, Goldberg A, Hovingh K, Cohen J, Karalis DG. J Gen Intern Med. 2020;35(7):2225-2227.
Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis.
Hu P, Dharmayat KI, Stevens CAT, et al. Circulation. 2020;141(22):1742-1759.
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
Kastelein JJ, Ginsberg HN, Langslet G, et al. Eur Heart J. 2015;36(43):2996-3003.
Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia.
Khera AV, Won HH, Peloso GM, et al. J Am Coll Cardiol. 2016;67(22):2578-2589.
Angiopoietin-like protein 3 (ANGPTL3) inhibitors in the management of refractory hypercholesterolemia.
Kosmas CE, Bousvarou MD, Sourlas A, et al. Clin Pharmacol. 2022;14:49-59.
Treatment goals in familial hypercholesterolaemia—time to consider low-density lipoprotein-cholesterol burden.
Langslet G, Holven KB, Bogsrud MP. Eur J Prev Cardiol. 2021;29(17):2278-2280.
Prevention of atherosclerotic cardiovascular disease in children with familial hypercholesterolemia.
Peterson AL, McNeal CJ, Wilson DP. Curr Atheroscler Rep. 2021;23(10):64.
Evinacumab for homozygous familial hypercholesterolemia.
Raal FJ, Rosenson RS, Reeskamp LF, et al. N Engl J Med. 2020;383(8):711-720.
Existing and emerging therapies for the treatment of familial hypercholesterolemia.
Rosenson RS. J Lipid Res. 2021;62:100060.
Evolocumab in pediatric heterozygous familial hypercholesterolemia.
Santos RD, Ruzza A, Hovingh GK, et al. N Engl J Med. 2020;383(14):1317-1327.
A Self-Assessment CME Test
An Interactive Journey
A Multimedia Case Study
Mechanism-Based Strategies to Achieve Patient-Centered Care
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Translating Research Into Practice
Translating Reseach Into Practice
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Individualizing Evidence-Based Care
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices in Diagnosis and Management
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
A New Era in Precision Medicine
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
Consensus and Controversies on the Road to Precision Medicine
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
The PCP’s Role in Timely Recognition and Referral
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Debates and Discussions About Personalizing Patient Management
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Evolving Roles of GLP-1 Receptor Agonists
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
From Guideline Recommendations to Daily Clinical Decision-Making
Improving Patient Outcomes Through Shared Clinical Decision Making
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Looking Beyond Hemoglobin A1c
Improving Patient Outcomes Through Shared Clinical Decision Making
Digging Deep on Shared Decision-Making
What You Need to Know
Mechanistic Insights and Evolving Treatment Options
Clinical Resource Center
Implications for PCSK9 Inhibitors in Clinical Practice
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
Mechanistic Insights and Emerging Treatment Options
A PrEP Primer
A Foundation for Managed Care
A Focus on Exacerbation Prevention
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
What the Pharmacist Needs to Know about PrEP
Unlocking Novel Paths to Patient Care
Evolving Best Practices for Patient Management
The Increasing Role of JAK Inhibitors
Shared Decision-making in the Era of Biologics
New Pathways to Patient Management
From Comprehensive Patient Evaluations to Individualized Evidence-based Care
Preventing COPD Exacerbations to Improve Outcomes
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Evolving Best Practices for Pediatric Patients
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
New Pathways to Optimize Patient Outcomes
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
Debates and Discussions About New Upstream Treatment Avenues
A Case-Based Update on Pediatric Patients
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
What You Need to Know About New Blood-Based Screening Tools
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Multidimensional Outcomes With SGLT2 Inhibitors
New Avenues to Improve Patient Outcomes
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Practical Updates on the 2023 GOLD Guidelines
A Phone-a-Friend CME Series – Volume 2
Incorporating New Data and Updated Guidelines Into Daily Practice
Focus on Psoriasis
Capitalizing on BCMA-Directed Therapies
From the Airway Epithelium to Improved Patient Outcomes
Exercising Best Practices for Hospitalized Patients
Accelerating Diagnosis and Treatment